Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vijay Aluri (NPI 1215979539)

Field	Value
Entity Type	Individual
Organization	Vijay Aluri
Address	202 10th St Se
City	Cedar Rapids
State	IA
ZIP	52403
Taxonomy	Rheumatology Physician
NPI Enumerated	June 12, 2006

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This practice is effectively single-payer: total Medicare revenue is $2M and there is no Medicaid billing on file, so Medicare dominates the provider’s public-payer footprint. The absence of any Medicaid claims suggests payer exposure and utilization patterns reported here are driven entirely by Medicare patients rather than a mixed Medicaid/Medicare panel.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top-three share is 54.9% of Medicare revenue, led by J3262 ($441.8K, 21.9%), J0129 ($403.8K, 20.0%), and J1602 ($263K, 13.0%). This concentration indicates that over half of Medicare receipts flow from a narrow set of infused or injected biologic therapies, making these agents the primary revenue drivers for the practice.

The code mix and descriptions point to a rheumatology practice built around in-office infusion and biologic administration: high-revenue biologic J3262 (tocilizumab), J0129 (abatacept), J1602 (golimumab) and presence of infusion/chemotherapy administration codes such as 96365 and 96413/96415 indicate routine supervised IV/subcutaneous drug delivery rather than only office-based E/M visits. Coupled with E/M codes (99214, 99215, 99205) and frequent lab panels, the pattern is consistent with longitudinal specialty management plus procedure-based infusion services.

Competitive standing by code is mixed but leans toward above-average utilization for several injectables. For example, J3262 ranks #75 of 618 (88th percentile) and is characterized in the file as "typical, unremarkable volume for this code," indicating a relatively high national position without being an outlier; similarly, J1745 ranks #107 of 1352 (92th percentile) and is also labeled "typical, unremarkable volume for this code," showing the provider is a high-volume user of some anti-TNF/infliximab therapies but not uniquely dominant.

Secondary biologic and immunomodulatory agents also contribute materially to revenue and reflect a broad therapy mix: J9312 (rituximab) generated $248.9K (12.3%) and ranks #116 of 317 (64th percentile, labeled "typical, unremarkable volume for this code"), while J0897 (denosumab) generated $160.9K (8.0%) and ranks #1355 of 10057 (86th percentile, labeled "typical, unremarkable volume for this code"). These figures suggest the practice deploys multiple classes of biologics rather than relying on a single molecule.

Infusion-administration and chemotherapy payment lines appear regularly in the billing profile, supporting an operational infusion capability: 96413 recorded 522 claims with $50.1K revenue (rank #612 of 7514, 92th percentile, labeled "typical, unremarkable volume for this code") and 96365 shows 264 claims with $12.1K. The presence and percentile positions of these codes indicate routine, billable infusion sessions are a meaningful part of patient care delivery rather than rare or incidental events.

High-percentile laboratory testing accompanies the drug/infusion footprint, consistent with monitoring needs for biologic therapy. Examples include 86140 (1.1K claims, $5.6K revenue, rank #215 of 4115, 95th percentile, labeled "typical, unremarkable volume for this code") and 82565 (1K claims, $5K revenue, rank #143 of 5066, 97th percentile, labeled "typical, unremarkable volume for this code"); these patterns suggest regular in-practice ordering or coordination of monitoring labs for treated patients.

The provider’s NPI tenure (enumerated 2006-06-12, ~20 years ago) combined with $2M lifetime Medicare revenue indicates an established specialty practice that has sustained biologic/infusion services over an extended period. For payers and competitors assessing network capacity, this profile signals a long-standing rheumatology infusion provider with concentrated Medicare exposure and no Medicaid volume to offset payer mix risk.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	88,350	$10	$441.8K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,880	$30	$403.8K
J1602	Injection, golimumab, 1 mg, for intravenous use	26,300	$10	$262.9K
J9312	Injection, rituximab, 10 mg	3,950	$60	$248.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	9,470	$30	$246.2K
J0897	Injection, denosumab, 1 mg	8,940	$20	$160.9K
J3111	Injection, romosozumab-aqqg, 1 mg	9,030	$10	$72.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$100	$50.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	510	$90	$45.8K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	260	$50	$12.1K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Vijay Aluri — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3262	2	10	35,440	$1	$233.1K
J0129	3	20	5,950	$30	$218.3K
J9312	1	10	3,190	$60	$198.4K
J1602	2	10	13,010	$10	$153.6K
J3111	13	20	12,180	$10	$112K
J1745	1	20	3,460	$30	$92.3K
J0897	22	190	1,920	$20	$74.1K
96413	12	80	210	$90	$24K
99214	476	4,690	100	$70	$14.4K
83970	22	50	40	$40	$8.3K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vijay Aluri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rochester General Hospital	NY	General Acute Care Hospital	$0	$226.8M
Rochester General Hospital-lab	NY	Clinical Medical Laboratory	$0	$33.4M
Rochester General Hospital	NY	Family Medicine Physician	$0	$25.2M
Rochester General Hospital	NY	General Acute Care Hospital	$0	$21.7M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0

Nearby Providers

Other providers in the same ZIP code as Vijay Aluri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Medical Center	IA	General Acute Care Hospital	$0	$26.4M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$24.5M
Eastern Iowa Health Center	IA	Family Medicine Physician	$0	$18.5M
Eastern Iowa Health Center	IA	General Practice Dentistry	$0	$14.4M
Linn County Emergency Medicine PC	IA	Emergency Medicine Physician	$0	$9.8M
C R Iv Service Inc	IA	Home Infusion Therapy Pharmacy	$0	$5.8M
Mercy Medical Center	IA	Cardiovascular Disease Physician	$0	$5.1M
Physicians' Clinic Of Iowa, PC	IA	Surgery Physician	$0	$4.9M
C R Pharmacy Service Inc	IA	Oxygen Equipment & Supplies (DME)	$0	$2.4M
Bogdan Cherascu	IA	Rheumatology Physician	$2.4M	$0

Vijay Aluri — Billing Profile & Reimbursement Data

Sign up for Vijay Aluri — Billing Profile & Reimbursement Data policy alerts

Vijay Aluri — Billing Profile & Reimbursement Data

Sign up for Vijay Aluri — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References